hydroxyindoleacetic acid has been researched along with Scleroderma, Systemic in 5 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An association between the ingestion tryptophan and a syndrome characterized by scleroderma-like skin abnormalities, fasciitis, and eosinophilia has recently been recognized in the United States." | 7.68 | Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. ( Heyes, MP; Maize, JC; Quearry, B; Silver, RM; Sternberg, EM; Vionnet-Fuasset, M, 1990) |
| "An association between the ingestion tryptophan and a syndrome characterized by scleroderma-like skin abnormalities, fasciitis, and eosinophilia has recently been recognized in the United States." | 3.68 | Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. ( Heyes, MP; Maize, JC; Quearry, B; Silver, RM; Sternberg, EM; Vionnet-Fuasset, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| TUFFANELLI, DL | 1 |
| Stachów, A | 2 |
| Jabłońska, S | 1 |
| Skiendzielewska, A | 2 |
| Kreysel, HW | 1 |
| Meyerhoff, K | 1 |
| Kimmig, J | 1 |
| Jablonska, S | 1 |
| Silver, RM | 1 |
| Heyes, MP | 1 |
| Maize, JC | 1 |
| Quearry, B | 1 |
| Vionnet-Fuasset, M | 1 |
| Sternberg, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| L-5-Hydroxy-Tryptophan-Related Eosinophilia-Myalgia Syndrome (EMS): Clinical Patient Evaluation[NCT00001918] | 20 participants | Observational | 1999-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for hydroxyindoleacetic acid and Scleroderma, Systemic
| Article | Year |
|---|---|
URINARY 5-HYDROXYINDOLEACETIC ACID EXCRETION IN SCLERODERMA.
Topics: Body Fluids; Hydroxyindoleacetic Acid; Indoleacetic Acids; Scleroderma, Systemic; Urine | 1963 |
Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma.
Topics: Colorimetry; Female; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Male; Monoamine Oxidase; | 1979 |
[Tryptophan-load in progressive scleroderma (author's transl)].
Topics: 3-Hydroxyanthranilic Acid; Female; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Kynurenine; | 1976 |
5-Hydroxytryptamine and tryptamine pathways in scleroderma.
Topics: Adolescent; Adult; Aged; Female; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids; Indoles; Male | 1977 |
Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan.
Topics: Adult; Aged; Eosinophilia; Fascia; Fasciitis; Female; Humans; Hydroxyindoleacetic Acid; Kynurenine; | 1990 |